

May 13, 2020



Syros to Present New Preclinical Data on SY-5609 at ASCO Virtual Scientific Program

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new preclinical data on the anti-tumor activity of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, in models of colorectal cancer. These data will be presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program (ASCO20) taking place May 29-31. Syros will also present on the design of its ongoing Phase 1 trial of SY-5609 at ASCO20.

The abstracts for these presentation are now available online on the ASCO20 website, at <https://meetings.asco.org/>.

Details of the poster presentations are as follows:

Presentation Title: Activity of SY-5609, an oral, noncovalent, potent, and selective CDK7 inhibitor, in preclinical models of colorectal cancer

Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Presenter: Liv Johannessen, Ph.D., Syros

Abstract Number: 3585

Poster Number: 315

Presentation Title: First-in-human phase I study of SY-5609, an oral, potent, and selective noncovalent CDK7 inhibitor, in adult patients with select advanced solid tumors

Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Presenter: Kyriakos P. Papadopoulos, M.D., South Texas Accelerated Research Therapeutics (START)

Abstract Number: TPS3662

Poster Number: 392

Presentations will be available for on-demand viewing on the ASCO20 website beginning May 29, 2020, at 8 a.m. EDT.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust pipeline, including SY-1425, a

first-in-class oral selective RAR α agonist in a Phase 2 trial in a genomically defined subset of acute myeloid leukemia patients, and SY-5609, a highly selective and potent oral CDK7 inhibitor in a Phase 1 trial in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20200513005806/en/>

Media:

Naomi Aoki
Syros Pharmaceuticals
617-283-4298
naoki@syros.com

Investors:

Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Source: Syros Pharmaceuticals